In an effort to understand the details of opioid ligandreceptor interactions and the basis for observed differences in ligand structure activity (SAR) profiles at different opioid receptor subtypes, we have, over the past several years, followed two complementary paths. The first of these was directed toward elucidation of the bioactive conformation(s) 329
of conformationally restricted ligands selective for individual opioid receptor subtypes, while the second path was focused on the development of a reliable, accurate method for modeling the three-dimensional structure of the opioid receptors. Successful completion of these aims would allow the development of realistic models for the precise interactions of specific opioid ligands with individual opioid receptor subtypes, from which an understanding of the structural basis of receptor selectivity could follow. This, in turn, would provide a reasonable starting point for structure-based design of more potent and/or more selective opioid ligands.
Our efforts have been focused primarily on l and d opioid receptor ligands and have been simplified by the development in our laboratory of two structurally related, conformationally constrained peptide series that differ markedly in their d vs. l receptor binding preferences.
Results of conformational analyses, via NMR, X-ray crystallography, and molecular mechanics, as well as structure)activity differences in these series, which allow structural features underlying the relative receptor selectivity of the two series to be inferred, are summarized below. Also summarized below is the method we developed for structural modeling of the transmembrane 7-helical bundle of G-protein-coupled receptors (GPCRs) and its application to the l and d opioid receptors. The more recent publication of the X-ray structure of rhodopsin, the prototypical GPCR, confirmed the primary details of our GPCR models and allowed an alternative starting point for development of l and d receptor models. (Fig. 1) . Conformational analysis, using both experimental and computational approaches, revealed that, although the 11-membered, tripeptide cycle within JOM-13 is indeed conformationally well defined, the exocyclic Tyr Figure 2 shows the proposed bioactive conformation of JOM-13.
While the JOM-13 series SAR was evolving, we examined related analogs in which different cyclization approaches were employed to allow variation in ring size, while maintaining the d-Cys-Phe-d-Pen tripeptide cycle (2). This was achieved by cyclizing as a dithioether (rather than the disulfide of JOM-13), which allows larger ring sizes to be readily explored. We discovered that simply replacing the 11-membered disulfide of JOM-13 by a 13-membered ethylene dithioether improved l receptor binding affinity and decreased d affinity (2) . If this peptide is further modified by replacing the C-terminal carboxylate with a carboxamide (long known to favor l vs. d binding), the resulting com-
displays high l binding affinity and moderate l selectivity (2). The combined result of two modifications (changes in ring size and C-terminus) is a 6000-fold selectivity shift (JOM-13:
Elucidation of the bioactive conformation of JOM-6 at the l opioid receptor was pursued in the same manner as that of JOM-6 at the d receptor ( We recently developed alternative opioid receptor models using the rhodopsin X-ray structure as a template for the inactive state of these receptors. To retain the orientation of polar, conserved and functionally important residues inside the TM domain the distortions present in the rhodopsin structure in TM5 (a-aneurism at H211) and TM7 (2 turns of 3-10 helix near K296) were reproduced in the opioid receptor models, while the a-aneurism in TM2 (near G90) was omitted. Because the X-ray structure of rhodopsin reflects the inactive state of the receptor, structural alterations accompanying activation must be incorporated to obtain a realistic active-state receptor structure. For example, the active state must reproduce the observed changes in distance between residues V139 (TM3) and C247, C252
(TM6) during rhodopsin activation (13) (14) (15) . 
Peptide synthesis
All peptides were prepared using standard solid-phase methods similar to those described previously for the synthesis of JOM-6 (2), using chloromethylated polystyrene (Merrifield) resin cross-linked with 1% divinylbenzene. Trifluoroacetic acid (TFA) was used for deprotection, and dicyclohexylcarbodiimide (DCC) and 1-hydroxybenzotriazole (HOBt) were employed to facilitate coupling. Alphaamino functions were t-butyloxycarbonyl (Boc) protected, and p-methylbenzene protection was employed for the labile side chain sulfhydyl groups of Cys and Pen. Simultaneous deprotection and cleavage from the resin were accomplished by treatment with anhydrous hydrogen fluoride in the presence of 5% p-cresol and 5% p-thiocresol.
Cyclization to dithioether-containing analogs was accomplished by treatment of a dilute solution of the linear free sulfhydryl-containing species in dimethyl formamide with potassium tert-butoxide followed by addition of dibromoethane. All peptides were then purified by RP-HPLC. Final product confirmation was obtained by fast atom bombardment mass spectrometry (FAB-MS).
Site-directed mutagenesis
Single, double and triple point mutations of the l opioid receptor were generated from the l/pCMV expression vector using the QuickChange Mutagenesis Kit (Stratagene, La Jolla, CA, USA). Each mutation was verified by DNA sequencing.
Cell culture and transfection
Cos-1 cells were grown in Dulbecco's modified Eagle's medium (high glucose) supplemented with 10% FBS and incubated at 37°C in 5% CO 2 . At 80% confluency, the cells were transiently transfected with 8-10 lg per 75 cm 2 flask of the wild-type and l opioid/pCMV mutants using Lipofectamine Plus reagent (20 and 30 lL of Plus reagent and Lipofectamine, respectively).
Cos-1 membranes
Forty-eight hours after transfection, the Cos-1 membranes were prepared for assay as described previously (21) . Briefly, the Cos-1 cells were scraped into 50 mm Tris)HC1, pH 7.4 containing 0.1 lg/mL PMSF (ice-cold) and homogenized using a Polytron homogenizer. Following centrifugation at 15 000 g for 30 min at 4°C, the membranes were resuspended to a concentration of 0.2 lg/mL in the homogenization buffer.
Radioligand binding assays
We used 40-50 lg of the membrane preparations in 200 lL for all binding studies. For all binding assays, the membranes were incubated with 25 lL aliquots of [ 
